Haleon PLC (GB:HLN) has released an update.
Haleon PLC, in conjunction with Pfizer Inc.’s offering to institutional investors, has agreed to an off-market purchase of approximately £230 million in ordinary shares, aiming to cancel about £114.6 million of them as part of its 2024 share buyback programme. The remaining shares worth roughly £115.4 million will be held as treasury shares to meet employee share plan commitments for 2025. The move is part of Haleon’s strategy to improve shareholder value and optimize its capital structure.
For further insights into GB:HLN stock, check out TipRanks’ Stock Analysis page.
